MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fped.2024.1375493

Медицинская библиотека · Frontiers in pediatrics · 2024

Mesenchymal stromal cells in the treatment of pediatric hematopoietic cell transplantation-related complications (graft vs. host disease, hemorrhagic cystitis, graft failure and poor graft function): a single center experience.

Pérez-Torres Lobato Maria, Benitez-Carabante Maria Isabel, Alonso Laura, Torrents Silvia, Castillo Flores Nerea, Uria Oficialdegui Maria Luz, Panesso Melissa, Alonso-Martínez Carla, Oliveras Maria, Renedo-Miró Berta, Vives Joaquim, Diaz-de-Heredia Cristina

СтатьяПеревод в очереди

Аннотация

OBJECTIVES

To describe mesenchymal stromal cells (MSCs) in the treatment of hematopoietic stem cell transplantation (HSCT) complications and to assess its safety and efficacy.

METHODS

Single-center retrospective study (2016-2023). Patients under 20 years who received MSCs for the treatment of HSCT-related complications were included.

RESULTS

Thirty patients (53.7% boys), median age at transplant 11 years (range 2-19) were included. MSCs indications were: graft-vs.-host disease (GVHD) in 18 patients (60%), of them 13 had acute GVHD (43.3%) and 5 chronic GVHD (16.7%); Grade 3-4 hemorrhagic cystitis (HC) in 4 (13.3%); poor graft function (PGF) in 6 (20%), 5 of them receiving MSCs with a CD34 stem cell-boost coinfusion; graft failure (GF) in 2 (6.7%), to enhance engraftment after a subsequent HSCT. Infusion-related-adverse-events were not reported. Overall response (OR) was 83% (25/30); 44% of responders (11/25) showed complete response (CR). OR for GVHD, HC, PGF and GF was 83.3%, 100%, 66.7% and 100% respectively. Response rate was 40% (95% CI: 20-55) and 79% (95% CI: 57-89) at 15 and 30 days. With a median follow-up of 21 months (IQR11-52.5), overall survival (OS) was 86% (95% CI: 74-100) and 79% (95% CI: 65-95) at 6 and 12 months post-MSCs infusion.

CONCLUSION

In our study, the most frequent indication of MSCs was refractory aGVHD (43.3%). Response rates were high (OR 83%) and safety profile was good.

Для цитирования: Pérez-Torres Lobato Maria, Benitez-Carabante Maria Isabel, Alonso Laura, Torrents Silvia, Castillo Flores Nerea, Uria Oficialdegui Maria Luz, Panesso Melissa, Alonso-Martínez Carla, Oliveras Maria, Renedo-Miró Berta, Vives Joaquim, Diaz-de-Heredia Cristina. Mesenchymal stromal cells in the treatment of pediatric hematopoietic cell transplantation-related complications (graft vs. host disease, hemorrhagic cystitis, graft failure and poor graft function): a single center experience.. Frontiers in pediatrics. 2024. DOI: 10.3389/fped.2024.1375493.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.